FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
about
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in RatsActivation of FXR protects against renal fibrosis via suppressing Smad3 expression.The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.Novel treatment options for portal hypertension.How to Face Chronic Liver Disease: The Sinusoidal Perspective.Angiotensin II induces connective tissue growth factor expression in human hepatic stellate cells by a transforming growth factor β-independent mechanism.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.Microbiota, cirrhosis, and the emerging oral-gut-liver axis.Drugs and Targets in Fibrosis.Bile acids at the cross-roads of gut microbiome-host cardiometabolic interactions.The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury.Phytosterols Synergize With Endotoxin to Augment Inflammation in Kupffer Cells but Alone Have Limited Direct Effect on Hepatocytes.Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.Cholestatic liver diseases: new targets, new therapiesAdapted Immune Responses of Myeloid-Derived Cells in Fatty Liver Disease
P2860
Q36242886-F37C1D52-BF7B-4192-AE42-3068FE863067Q37419118-3A01E54C-40AE-4C27-9ABE-9FB9D1735BB8Q38659340-5A2BA750-3989-4E00-99AE-D9BEB959B61CQ38680437-7DFCE723-95EC-4F0A-89DE-0F119F6C3AF3Q38940706-97C9B083-32CB-4B30-A613-51049A887137Q41353200-C310345F-4E9B-4388-8EDF-3B39A4E111D1Q42695159-D547616F-8E24-46AE-B6B9-7BA44DE89D9AQ45069266-E532FD1B-579F-4F74-B1B6-3ED44DF13D78Q47119118-980F17E9-25A1-45C2-B4D7-907BF470556FQ47134180-1C61D6F8-2CE5-42FD-AE22-7D4377AD4BE6Q48217956-3C9B33DF-EC05-4C3F-B987-C4F2EB85064CQ52759572-F4318D6B-76B4-4360-828B-765AC2A7022DQ55278681-80FB45FA-1954-40D4-848D-8DDFD0FFFA47Q57111104-692012C7-A957-4387-9395-3971CCDDD663Q58596151-E63A837F-3AA5-48FC-8D0B-707EF067F0B3
P2860
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
FXR agonist obeticholic acid r ...... a rat model of toxic cirrhosis
@en
type
label
FXR agonist obeticholic acid r ...... a rat model of toxic cirrhosis
@en
prefLabel
FXR agonist obeticholic acid r ...... a rat model of toxic cirrhosis
@en
P2093
P2860
P50
P356
P1433
P1476
FXR agonist obeticholic acid r ...... a rat model of toxic cirrhosis
@en
P2093
Frederik Nevens
Ingrid Vander Elst
Jonel Trebicka
Len Verbeke
Mathias Wenes
Petra Windmolders
Sabine Klein
P2860
P2888
P356
10.1038/SREP33453
P407
P50
P577
2016-09-16T00:00:00Z